SAVA Q3 2025 Earnings — Cassava Sciences, Inc. Revenue & Financial Results | Market Cap Arena

SAVACassava Sciences, Inc.

$116M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$200,000

Operating Income

-$12M

Net Income

-$11M

EPS (Diluted)

$-0.22

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$130M

Total Liabilities

$48M

Stockholders' Equity

$82M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$200,000	-$18M	+98.9%
Operating Income	-$12M	-$31M	+61.3%
Net Income	-$11M	-$28M	+61.3%